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Abstract:  CMX001  (phosphonic  acid,  [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-
(hydroxymethyl)ethoxy]methyl]mono[3-(hexadecyloxy)propyl] ester) is a lipid conjugate 
of the acyclic nucleotide phosphonate, cidofovir (CDV). CMX001 is currently in Phase II 
clinical  trials  for  the  prophylaxis  of  human  cytomegalovirus  infection  and  under 
development  using  the  Animal  Rule  for  smallpox  infection.  It  has  proven  effective  in 
reduction of morbidity and mortality in animal models of human smallpox, even after the 
onset of lesions and other clinical signs of disease. CMX001 and CDV are active against 
all five families of double-stranded DNA (dsDNA) viruses that cause human morbidity and 
mortality, including orthopoxviruses such as variola virus, the cause of human smallpox. 
However, the clinical utility of CDV is limited by the requirement for intravenous dosing 
and  a  high  incidence  of  acute  kidney  toxicity.  The  risk  of  nephrotoxicity  necessitates 
pre-hydration and probenecid administration in a health care facility, further complicating 
high volume CDV use in an emergency situation. Compared with CDV, CMX001 has a 
number of advantages for treatment of smallpox in an emergency including greater potency 
in vitro against all dsDNA viruses that cause human disease, a high genetic barrier to 
resistance, convenient oral administration as a tablet or liquid, and no evidence to date of 
nephrotoxicity in either animals or humans. The apparent lack of nephrotoxicity observed 
with  CMX001  in  vivo  is  because  it  is  not  a  substrate  for  the  human  organic  anion 
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transporters that actively secrete CDV into kidney cells. The ability to test the safety and 
efficacy of CMX001 in patients with life-threatening dsDNA virus infections which share 
many basic traits with variola is a major advantage in the development of this antiviral for 
a smallpox indication. 
Keywords: CMX001; smallpox; dsDNA virus; antiviral; cidofovir; variola 
 
1. Introduction 
Variola virus, the etiologic agent of smallpox, is a CDC Category A pathogen. Smallpox is one of 
the most pestilent diseases feared by mankind since antiquity, and historically has been associated with 
the periodic occurrence of widespread, often devastating epidemics. The fatality rate associated with 
the disease was reported to be roughly 30%, and a significant number of survivors were disfigured 
and/or blinded. However, historical data were derived from a population in which the disease was 
endemic.  The  last  naturally  acquired  case  of  smallpox  occurred  in  1977  and  the  last  laboratory 
acquired infection in 1978 [1]. In 1980, the World Health Organization (WHO) reported that, due to 
their aggressive worldwide vaccination program, smallpox had been eradicated [2]. Subsequent to this 
declaration, the worldwide vaccination campaign was stopped (the last vaccinations of the general 
population  in  the  United  States  were  in  1972  and  in  the  rest  of  the  world  in  1984)  because  of  
side effects associated with smallpox vaccine [2]. As a result, herd immunity has been lost in the 
ensuing  30+  years,  leaving  most  of  the  world’s  population  highly  vulnerable  to  morbidity  and 
mortality from variola infection. 
In the wake of the terrorist attacks on September 11, 2001, and the anthrax attacks using the U.S. 
Postal Service to deliver letters containing Bacillus anthracis in October of 2001, the United States 
began in earnest to consider the impact of reintroduction of smallpox via a deliberate release into a 
highly susceptible population. Within weeks of September 11, 2001, the U.S. government decided to 
purchase adequate smallpox vaccine, 300 million doses, to immunize the entire population of the 
United States. If the public health infrastructure is prepared for the release of smallpox into the general 
population, many people could indeed be protected by vaccination. However, if vaccination is delayed 
by as few as three to four days after exposure, there may be little benefit. As in the case of mortality 
figures, the impact of delay on the development of a protective immune response after vaccination is 
based  on  observations  made  during  the  WHO  eradication  campaign  under  natural  transmission 
conditions in a population in which the disease was endemic [3]. The impact of infection with a large 
inoculum of variola virus on the window of opportunity for vaccinating primary cases is unknown in 
the current highly susceptible population. In any event, many secondary cases of smallpox will likely 
occur and the disease could become widespread before primary cases of smallpox are identified, in 
part due to the lack of familiarity of disease signs and symptoms among the current generation of 
healthcare professionals. Diagnosis for public health response purposes will most likely be made after 
the onset of lesional disease. Consequently there is a need for antiviral drugs to treat patients who are 
diagnosed  with  smallpox  after the appearance of lesions.  Ultimately  the  same  drugs will be  used 
prophylactically/preemptively  in  exposed  but  asymptomatic  populations  to  delay  the  progression  Viruses 2010, 2                         
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of  infection  and  increase  the  window  of  opportunity  for  vaccination  and  the  development  of  
protective immunity. 
In response to the threat of variola release, the Interagency Working Group on smallpox, a U.S. 
government group made up of officials at the Assistant Secretary level, recommended in 1998 that two 
antiviral drugs for treating smallpox with different mechanisms of action be developed. At least one of 
these drugs was to be orally available [4]. However, in addition to the indication for the treatment of 
smallpox in the general population, the drug would be the first line of defense for the tens of millions 
of people who are at risk of life-threatening vaccinia infections if vaccinated with a live attenuated 
virus  vaccine  such  as  the  currently  stockpiled  ACAM2000.  These  populations  include  pregnant 
women and many groups of patients whose immune systems are weakened (e.g., AIDS patients, organ 
transplant  recipients  and  patients  on  cancer  therapy).  Another  possible  threat  is  suggested  by  the 
demonstration that genetically engineered interleukin (IL)-4-positive strains of mousepox virus are 
lethal  in  mice,  despite  prior  vaccination  [5].  This  modification,  if  applied  to  variola  virus,  could 
produce a strain that causes severe illness or death even in the vaccinated population. It is clear that the 
complete defense of the country against a terrorist attack using variola virus, whether modified or not, 
requires safe, easily administered antiviral drugs ready for use in the Strategic National Stockpile. 
2. The Ideal Product Profile for Use in a Public Health Emergency 
The  Department  of  Health  and  Human  Services  through  the  Biomedical  Advanced  Research  and 
Development Authority (BARDA) issued a request for proposals in March of 2009 (RFP-BARDA-09-35) 
to provide a medical countermeasure that could specifically treat symptomatic individuals exposed to 
smallpox. Beyond stating that the product acquired under this contract must be able to ―support a 
public health emergency‖, no specific properties, performance criteria or therapeutic profile in humans 
were specified. In the absence of specific guidance on product profile we identified the properties 
listed below as being essential for a drug to be highly effective in a public health emergency.  
Potency: Clinically, potency is best defined as the relationship between the concentration of drug 
achieved in the plasma and the intensity of the therapeutic effect of the drug [6]. In the case of a 
medical countermeasure to treat an acute viral infection in a public health emergency, the potency 
needs to be such that at a level of drug that is easily and reproducibly achieved in the plasma of sick 
patients, the antiviral effect is adequate to quickly reduce viral burden thereby reducing the morbidity 
of the infection and, owing to reduced viral shedding, limiting infectivity.  
Schedule: The course of therapy necessary to suppress the virus long enough for the host adaptive 
immune response to develop should be as short as possible and the dosing regimen should be simple 
and easy to follow to ensure compliance in a public health emergency.  
Risk of Resistance: Emergence of a resistant virus post attack may allow the unchecked spread of 
disease through the population. The probability that a rapidly replicating virus circulating through a 
highly susceptible population during an epidemic would develop resistance is high. Resistance has 
developed  to  every  widely  used  antiviral  drug  to  date  and  has  had  a  profound  impact  on  the 
development of new antiviral agents [7]. The best approach to limiting viral breakthrough has been to 
develop potent drugs that target key replication proteins (enzymes) with a high genetic barrier to Viruses 2010, 2                         
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resistance. In addition, the resistant virus that ultimately emerges from such targeted drugs may be 
non-virulent,  especially  if  mutations  in  the  active  site  of  a  critical  enzyme  are  required  for  the 
development of clinical resistance.  
Drug-Drug  Interaction:  Antiviral  therapy  during  a  smallpox  attack  would  be  used  for  the 
treatment/prophylaxis of: (1) immunosuppressed patients who were exposed and are symptomatic with 
smallpox and, (2) those who received smallpox vaccination, developed complications from the vaccine 
and  consequently  need  antiviral  therapy. These  groups of  people will typically require significant 
medical management and be on multiple medications. The ideal smallpox antiviral will need to have 
minimal  potential  for  drug  interactions  and  will  not  require  dosage  adjustment  in  patients  taking 
multiple concomitant medications. 
Formulation Characteristics: The manufacturing process for the drug needs to be robust with the 
potential  to  accommodate  surge  capacity  if  necessary.  The  dose  formulation  should  be  easy  to 
produce, and stable for long-term storage under a range of conditions. 
These properties represent the context in which we are developing CMX001 as a potential medical 
countermeasure for use in a smallpox attack. 
3. CMX001 in vitro Efficacy and Resistance Testing 
CMX001 is active in vitro against a broad range of viruses from all five families of dsDNA viruses 
infecting humans, including multiple species of Orthopoxviridae. As shown in Table 1, conjugation of 
the lipid to the phosphonate moiety of CDV to produce CMX001 results in significant decreases in 
apparent EC50 values relative to those observed for CDV. In the case of the orthopoxviruses, the 
enhancement in activity (determined as the ratio of the EC50 CDV/EC50 CMX001) ranges from a high 
of  271-fold  for  variola  virus  to  a  low  of  24-fold  for  ectromelia  virus.  The  increased  activity  of 
CMX001 relative to CDV is attributable to the more efficient cellular uptake of CMX001 facilitated by 
the  lipid  chain  [8].  CDV  is  transported  into  cells  by  a  relatively  inefficient  method,  fluid  phase 
endocytosis [9]. 
CMX001  (Figure  1a)  is  formed  by  conjugating  a  lipid,  3-hexadecyloxy-1-propanol,  to  the 
phosphonate  moiety  of  CDV.  Once  CMX001  is  inside  cells,  CDV  (Figure  1b)  is  liberated  by 
phospholipase cleavage of the lipid ester linkage and activated by two successive phosphorylations, 
first to cidofovir monophosphate (CDV-P, Figure 1c) and then to cidofovir diphosphate (CDV-PP, 
Figure 1d) [10]. The CDV-PP acts as a competitive, alternative substrate inhibitor of the DNA directed 
DNA  polymerases  encoded  by  the  herpesvirus,  adenovirus  and  orthopoxvirus  families  of  
double-stranded DNA viruses (dsDNA) [11–14]. 
The broad spectrum activity of CMX001 against various species of orthopoxviruses was anticipated 
based  on  the  mechanism  of  action  of  the  drug,  inhibition  of  the  virally  encoded  polymerase  by  
CDV-PP, and the high level of homology for this enzyme seen within the family. The amino acid 
sequences of the catalytic subunit of the polymerase have been aligned for cowpox virus (CPXV, 
strain Brighton Red), ECTV (strain Moscow), MPXV, (strain Zaire 1979-005), VACV (strains 3737 
and Western Reserve), RPXV (strain Utrecht) and VARV (strains Bangladesh 1975 and India 7129). 
All of the subunits are 1005 residues in length, completely overlap, and have sequence identity ranging 
from 98.2% to 99.1%. Sequences were obtained from Poxvirus Bioinformatics Resource Center [15] Viruses 2010, 2                         
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and aligned with the NCBI Protein Blast program, BLASTP 2.2.24, [16]. This level of similarity in the 
target enzyme also supports the use of surrogates for VARV in the animal model studies required 
under the Animal Rule (21 CFR 314.600) to establish the efficacy of CMX001, or more specifically 
the efficacy of CDV-PP, the active antiviral formed from CMX001 (Figure 1). 
Table 1. The in vitro activity of CMX001 and CDV against viruses in all five families of 
dsDNA viruses known to cause human morbidity and mortality. 
Viral Class  Virus (ref)  CMX001 
EC50 (µM) 
CDV 
EC50 (µM) 
Enhanced Activity 
(EC50 CDV/EC50 CMX001) 
Adenovirus  AdV 5 [17]  0.02  1.3  65 
Herpesvirus 
HSV 1 [18]  0.06  15  250 
HHV 6 [18]  0.004  0.2  50 
CMV [18]  0.0009  0.38  422 
VZV [18]  0.0004  0.5  1250 
EBV [18]  0.04  >170  >4250 
Papillomavirus  HPV 11 [19]  17  200  12 
Polyomavirus 
BKV [20]  0.13  115.1  885 
JCV [21]  0.045  nd  n/a 
Orthopoxvirus 
VARV [22]  0.1  27.3  271 
VACV [23]  0.8  46  57 
ECTV [24]  0.5  12  24 
RPXV [25]  0.5  39  78 
MPXV [22]  0.07  4.6  65 
nd: not determined; n/a: not applicable; Abbreviations for viruses: AdV, adenovirus; HSV, herpes 
simplex virus; HHV, human herpes virus; CMV, human cytomegalovirus; VZV, varicella-zoster 
virus;  EBV,  Epstein-Barr  virus;  HPV,  human  papillomavirus;  BKV,  BK  virus;  JCV,  JC  virus; 
VARV,  variola  virus;  VACV,  vaccinia  virus;  ECTV,  ectromelia  virus;  RPXV,  rabbitpox  virus; 
MPXV, monkeypox virus; cowpox virus, CPXV. 
 
In vitro experiments to generate orthopoxvirus strains resistant to CDV have been conducted and 
cross-resistance to CMX001 examined. Serial passage studies of camelpox, CPXV, MPXV and VACV 
viruses with CDV have all generated resistant strains [26]. The extent of viral resistance is reported to 
be  on  the  same  order  as  that  observed  for  CDV-resistant  forms  of  herpes  simplex  virus  and  
CMV (10 to 27-fold). Resistant strains of VACV (strain WR) generated after 20 to 30 passages in the 
presence of increasing concentrations of CDV have been shown to be cross resistant to CMX001 [27]. 
Mutations conferring this resistance are located in the virally encoded DNA polymerase. Additionally, 
the development of resistance to CDV and CMX001 in VACV leads to a significant attenuation of 
virulence in mice [28], suggesting that any mutants that might become dominant from drug pressure 
during treatment of smallpox would be attenuated and less virulent.  Viruses 2010, 2                         
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Figure 1. CMX001 cleavage and anabolism by host cell enzymes. 
 
 
Twelve  mutations  in  the  polymerase  domain  of  VACV  have  been  associated  with  phenotypic 
resistance to CDV as shown in Table 2. The specific roles of these mutations in CDV resistance have 
not been uniformly elucidated and some appear to be secondary; however, 11/12 of the sites involved 
are completely conserved among representative members of the orthopoxviruses suggesting the data 
obtained  in  VACV  can  be  extrapolated  to  other  members  of  this  family,  including  VARV.  This 
observation  is  in  accord  with  the  overall  high  level  of  sequence  homology  observed  across  the 
orthopoxviruses. 
Table 2. Mutations in the polymerase gene of VACV associated with CDV resistance. 
Amino  acid  numbering  is  according to  VACV strain WR DNA polymerase (GenBank 
accession No. P06856). 
Mutation(s)  CDV Fold Resistance  Author  Virulence in Mice 
∆K174  3 to 4  Becker [29]  Reduced 
A314T  5 to 7  Andrei [28]  Reduced 
A314V  7  Becker [29]  Reduced 
A684V  3 to 9  Andrei [28]; 
Gammon [30]  Reduced 
S851Y  2 to 3  Gammon [30]  Reduced 
H296Y/S338F  12  Kornbluth [27]  nd 
A314T/A684V  11 to 15  Andrei [28]  Reduced 
A314T/T688A  11 to 17  Andrei [28]  Essentially non-virulent 
A684V/S851Y  7 to 16  Gammon [30]  Reduced 
∆K174/M671I  4 to 5  Becker [29]  Reduced 
A314T/A684V/ Y232H  25  Andrei [28]  nd 
H296Y/A314V/ 
H319N/S338F/ R604S  11 to 14  Kornbluth [27]  Reduced 
nd: not done. Viruses 2010, 2                         
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4. Establishing Activity under the Animal Efficacy Rule 
Because  smallpox  has  been  eradicated,  the  effectiveness  of  anti-VARV  agents  cannot  be 
demonstrated in human clinical trials. In order to provide a development path for candidate smallpox 
therapeutics,  the  FDA  promulgated  the  ―Animal  Efficacy  Rule‖  in  June  of  2002  [31].  This  rule 
establishes conditions under which animal models can be used to provide evidence of the effectiveness 
of  an  antiviral  agent  to  treat  a  disease  or  condition  for  which  clinical  studies  are  impossible  or 
unethical.  
As described in 21 CFR 314, subpart I, FDA will accept data from studies in animal models as 
evidence of efficacy when the following criteria are met: ―(1) there is a reasonably well-understood 
pathophysiological  mechanism  of  the  toxicity  of  the  substance  and  its  prevention  or  substantial 
reduction by the product; (2) the effect is demonstrated in more than one animal species expected to 
react with  a  response predictive  for humans,  unless  the effect is  demonstrated in  a single animal 
species that represents a sufficiently well-characterized animal model for predicting the response in 
humans; (3) the animal study endpoint is clearly related to the desired benefit in humans, generally the 
enhancement  of  survival  or  prevention  of  major  morbidity;  (4)  the  data  or  information  on  the 
pharmacokinetics  and  pharmacodynamics  of  the  product  or  other  relevant  data  or  information,  in 
animals  and  humans,  allows  selection  of  an  effective  dose  in  humans.‖  Each  of  these  points  is 
discussed below in the context of the program to develop CMX001 under the Animal Efficacy Rule. 
4.1. Pathophysiological Mechanisms  
Although our understanding of the pathogenesis of variola virus infection in humans is limited, it is 
clear that viral replication plays a key role in the lethality of the infection. Historically, the mortality 
rate  from  ordinary-type  smallpox  was  approximately  30%  (5–50%).  Mortality  correlated  with  the 
density  of  pock  lesions  on  the  skin,  which  almost  certainly  correlated  with  the  intensity  of  the 
secondary viremia. Thus, an intervention that reduces viral replication should also reduce lesion count 
and increase survival. The antiviral mechanism by which CMX001 prevents or substantially reduces 
the toxicity of orthopoxviruses is understood. The drug arrests disease progression by blocking viral 
DNA replication and thereby reducing viral burden [13,30,32]. 
4.2. Efficacy in Animal Models 
The optimal model for a human virus infection is an animal that can be naturally infected with the 
same  virus;  however,  humans  are  the  only  natural  host  for  VARV.  Since  the  target  enzyme  of 
CMX001 is highly conserved, orthopoxviruses that naturally infect the model species are the next best 
choice.  These  natural  infections  have  several  hallmarks  that  may  make  them  more  desirable  than 
laboratory  contrived  infections,  including  low  virus  dose  infections  that  result  in  high  mortality, 
relevant routes to induce severe disease in immunocompetent hosts, and virus-encoded host response 
modifier genes matched to host processes. Epidemiological data suggest that VARV is most often 
transmitted in large respiratory droplets making respiratory transmission the most relevant [2]. There is 
also considerable evidence suggesting that VARV infection of humans is initiated with a small dose of 
virus [33]. Thus for a model, a low inoculum delivered via the upper respiratory tract is the preferred Viruses 2010, 2                         
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route of infection. Unfortunately, no single animal model meets these criteria and fully reproduces the 
clinical and pathogenic course of VARV infection in humans.  
Since there is no single model of orthopoxvirus infection that completely replicates the clinical and 
pathophysiological course of human smallpox, CMX001 has been tested extensively in mouse, rabbit, 
and  non-human  primate  models  of  orthopoxvirus  infection.  The  results  of  these  studies  are 
summarized below. 
CMX001  in  mouse  models  of  orthopoxvirus  infection—The  in  vivo  anti-orthopoxvirus  activity  of 
CMX001 has been extensively characterized in mice infected with ECTV, CPXV and VACV viruses. 
Ectromelia virus (mousepox) infection of mice has been used extensively as a model for orthopoxvirus 
pathogenesis and as a model for testing the efficacy of anti-orthopoxvirus therapeutics [34]. ECTV is a 
natural  pathogen  of  mice  and  depending  upon  the  mouse  strain  and  route  of  inoculation,  lethal 
infection can be initiated with a very small inoculum. Additionally, infection of mice with CPXV and 
VACV  can  be  used  to  assess  the  efficacy  of  an  antiviral  against  orthopoxviruses  that  can  infect 
humans. The availability of an animal model(s) to help establish an effective dose for the treatment of 
vaccinia  virus  is  critical  in  determining  the  potential  utility  of  a  drug  in  treating  the  side  effects 
associated with a vaccinia derived, live attenuated virus smallpox vaccine. 
A large number of CMX001 regimens have been studied in ECTV-infected A/NCR mice. In this 
model,  a  2.5  mg/kg  dose  of  CMX001  given  once  daily  for  five  days  starting  4  h  post-infection 
provides complete protection against a lethal intranasal challenge. When treatment is started as late as 
five days post-infection (3–4 days prior to the death of untreated controls), mice can be completely 
protected  from  mortality  with  a  loading  dose  of  10  mg/kg  followed  by  a  maintenance  dose  of 
2.5 mg/kg every other day for 14 days. A single 20 mg/kg oral dose of CMX001 given as late as four 
days post-infection provided 100% protection against lethal ECTV infection [35,36].  
Against CPXV infection, oral administration of 10 mg/kg of CMX001 daily for five consecutive 
days was 100% protective in mice infected by either the aerosol inhalation or intranasal route when 
dosing was initiated 4 h post-infection [22]. A single oral dose of 12.5 mg/kg was 80% protective 
when given as early as five days before exposure, 100% effective when given one or three days before 
exposure, 100% effective when given one day post–exposure, and 87% protective when given as late 
as three days post-exposure [37]. CMX001 therapy showed significant protection (86%) against lethal 
VACV infection when initiated as late as 24 h post-infection (mean day of death for vehicle controls  
was 6.8) [37]. 
CMX001 in a rabbitpox model—Rabbitpox virus is a subspecies of VACV that is naturally highly 
pathogenic in rabbits. Like other orthopoxvirus infections in their natural hosts, RPXV infection of 
rabbits shares many characteristics of smallpox. RPXV infection is readily transmitted between rabbits 
by the respiratory route and follows a pathophysiological progression similar to that of smallpox. 
Rabbits infected with RPXV undergo an incubation phase followed by the onset of fever, lesions, and 
ultimately respiratory distress and typically death [38]. Intradermal infection of rabbits allows for a 
controlled inoculum to be delivered while maintaining a course of disease nearly identical to that of 
the natural respiratory infection. Additionally, the lethal inoculum for intradermal infection is much 
lower than that required for intranasal infection, more closely mimicking the low inoculum required 
for human smallpox infection. Finally, intradermal infection results in a reliable occurrence of lesions, Viruses 2010, 2                         
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whereas with respiratory infection, rabbits sometimes die before rash development [39]. Ear lesions in 
the rabbitpox model, a result of systemic viral spread from the intradermal inoculation site on the 
thigh, typically appear beginning from  three to five days post infection. As the desired trigger to 
initiate therapy for the treatment of smallpox is the onset of lesions, the reliable occurrence of lesions 
is a distinct advantage. 
CMX001  has  been  studied  in  New  Zealand  White  rabbits  infected  intradermally  with  a  lethal 
inoculum of RPXV [38,40,41]. Initial studies established the efficacy of CMX001 for pre-exposure 
and  post-exposure  prophylaxis.  For  example,  100%  of  animals  administered  a  dose  of  10  mg 
CMX001/kg/day  for  five  days  survived  when  treatment  was  initiated  one  day  before  challenge 
compared  to  0%  survival  in  animals  administered  placebo  [38].  Delayed  treatment  experiments 
showed that CMX001 can be given late in the infection cycle, after appearance of clinical signs of 
disease (fever and lesions), and still prevent mortality. In a representative experiment, 100% of rabbits 
administered a dose of 10 mg CMX001/kg/day for five days survived when treatment was initiated 
four days after infection compared with 0% of placebo treated animals. Treatment initiated at five  
days post infection also provided a survival benefit (75% of CMX001-treated compared with 0% of 
placebo treated). 
In a series of randomized, blinded, placebo-controlled studies, administration of 20 mg/kg CMX001 
initiated at the onset of lesions in the ears (mean 3.8 days post infection, range three to five days) 
provided  a  survival  benefit  over  placebo-treated  animals  [40].  The  results  of  these  studies  are 
summarized  in  Table  3.  Even  a  single  dose  of  20  mg/kg  CMX001  given  at  the  onset  of  lesions 
provided  a  statistically  significant  survival  benefit  compared  to  placebo  [40].  Note  that  based  on 
AUC0–∞, the 20 mg/kg dose in rabbits equates to a 0.67 mg/kg dose in humans (see Table 4). Doses in 
this range have been used to successfully treat fulminate disseminated dsDNA infections in patients.  
Table  3.  Efficacy  of  CMX001  in  protecting  rabbits  from  mortality  following  a  lethal 
intradermal inoculation with rabbitpox virus. 
Treatment Regimen 
Total CMX001 
Dose 
CMX001 
Survivors 
Placebo 
Survivors 
P Value* 
3 doses of 20 mg/kg CMX001 
(1 dose every other day starting 
at onset of lesions) 
60 mg/kg  11/12  2/12  0.0006 
2 doses of 20 mg/kg CMX001 
(1 dose every other day starting 
at onset of lesions) 
40 mg/kg  8/12  1/12  0.0049 
1 dose of 20 mg/kg CMX001 
at onset of lesions: 
20 mg/kg  7/12  1/12  0.0272 
* 2-sided Fisher’s exact test. 
 
Monkeypox in Cynomolgus Monkeys—Infection of cynomolgus monkeys with MPXV produces an 
exanthematous disease that can be used to evaluate the effect of a drug on skin lesions, viremia, and 
mortality. Because this model requires a large intravenous (i.v.) dose of virus (1–5 × 10
7 PFU of 
MPXV)  to  achieve  a  severe infection  [42–45], the model may  not  reflect the pathophysiology  of 
human disease, where the infectious dose is thought to be on the order of 100 PFU [46]. Animals Viruses 2010, 2                         
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manifest the first signs of illness within two to five days after infection and die within nine to 17 days 
(compared  with  six  to  15  days  and  16  to  22  days,  respectively,  in  human  smallpox)  and  have  a  
near 100% mortality rate (as compared to 30% in humans). The distribution and progression of skin 
lesions in monkeys is similar to that in human smallpox. Although there may be a potential advantage 
to using a non-human primate as a model for a human disease, this advantage is offset by the very 
large intravenous inoculum required to induce severe disease.  
Table 4. Plasma Cmax and AUC of CMX001 and CDV after a single oral administration of 
CMX001 to animals and humans. 
Species 
Dose 
(mg/kg) 
CMX001  CDV 
Cmax 
(ng/mL) 
AUC0–∞ 
(h·ng/mL) 
DN
1 
AUC0–∞ 
Cmax 
(ng/mL) 
AUC0–∞ 
(h·ng/mL) 
DN
1 
AUC0–∞ 
Monkey  4  13  32  8  14  197  49 
Rat  4  14  141  35  9  280  70 
Mouse  10  69  403  40  11  175
2  17
2 
Rabbit  4  30  179  45  13  254
2  66
2 
Human  2  350  2650  1325  31  1740  870 
1  dose normalized; 
2  AUC0–24h. 
 
CMX001 was tested in the i.v. inoculation MPXV model at oral doses of 2.5, 5, and 10 mg/kg 
administered on days 1, 3, 6, 9, and 12 post–infection. Although these doses did not reduce mortality, 
an explanation was provided by pharmacokinetic analysis which showed that systemic exposure of 
cynomolgus monkeys to CMX001 following oral administration was very low compared to that seen 
in other species including mice, rabbits, and humans, with humans having by far the best systemic 
exposure (AUC) after oral administration (see Table 4). A subsequent study of MPXV in monkeys 
using intramuscular (i.m.) administration of CMX001 showed an equivocal effect of treatment, despite 
this route resulting in a higher systemic exposure to CMX001. This result was somewhat unexpected 
given that i.v. CDV had been shown to be effective in the model and that both CDV and CMX001 
produce the same active antiviral metabolite, CDV-PP. However, comparison of the levels of CDV-PP 
after  i.v.  CDV  treatment  versus  i.m.  CMX001  treatment  (in  healthy  monkeys)  revealed  that  the 
concentration of CDV-PP was much higher in the peripheral blood mononuclear cells (PBMCs) of 
animals treated with i.v. CDV compared to those treated with i.m. CMX001 (Figure 2). This result is 
consistent with intracellular conversion of CMX001 to CDV being inefficient in monkeys. Because of 
this metabolic difference between monkeys and humans, data obtained with CMX001 in monkeys 
cannot be used to model human exposure. To circumvent this issue, CDV treatment of monkeys will 
be used to model the exposure to the active antiviral metabolite, CDV-PP, which is common to both 
CDV and CMX001. This approach to using monkey model data to help establish a human dose is 
described under ―Selection of an Effective Dose in Humans‖ below. 
4.3. Selection of Endpoints 
With the exception of studies of VARV in monkeys where statistically powered mortality endpoints 
may  not  be  feasible,  the  primary  endpoint  in  animal  efficacy  studies  is  survival  to  42  days  post Viruses 2010, 2                         
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infection. This endpoint is clearly relevant to the desired benefit in humans. In VARV studies, due to 
the partial mortality in the model, the ethical concerns of using large numbers of monkeys to achieve 
statistical  significance,  and  the  practical  constraints  of  handling  large  numbers  of  monkeys  under 
biosafety level 4 conditions, the proposed primary endpoint is a reduction in the number of lesions. 
Historically, the mortality rate from ordinary-type smallpox was positively associated with the density 
of  pock  lesions,  which  almost  certainly  correlated  with  the  intensity  of  the  secondary  viremia.  
Thus,  an  intervention  that  reduces  viral  replication  should also  reduce  the number of lesions and 
increase survival. 
Figure 2. Concentrations of CDV-PP in PBMCs of healthy uninfected monkeys after i.v. 
administration  of  20  mg/kg  CDV  or  i.m.  administration  of  4  mg/kg  CMX001,  and  in 
PBMCs of rabbits after oral administration of 20 mg/kg CMX001. Dosing occurred on 
Days 1, 6, and 11 for monkeys and on Days 1, 3, and 5 for rabbits. For averaging purposes, 
samples  with undetectable  CDV-PP were assigned a value of zero. Samples that were 
below the limit of quantitation (BLQ), but had detectable CDV-PP, were included in the 
averages at the determined value. All samples from CMX001 dosed monkeys were BLQ. 
Error bars represent SEM. Monkey data N = 10–12; Rabbit data N = 3. 
 
 
4.4. Selection of an Effective Dose in Humans 
Straightforward use of different animal models of human smallpox for establishing the dose of a 
drug requires relatively consistent pharmacokinetic/pharmacodynamic profile of the drug across the 
animal model species. The pharmacokinetics (PK) of CMX001 have been determined in humans and 
in  all  animal  species  in  which  the  drug  has  been  used  to  study  orthopoxvirus  infection  to  date. 
Exposure to CMX001 after oral administration differs dramatically across species, with the lowest 
exposure occurring in monkeys and highest exposure occurring in humans (see Table 4). Even after 
achieving high plasma concentrations of CMX001 in monkeys by administration via non-oral routes, 
the conversion to the active moiety CDV-PP is low. The use of CDV as a surrogate for CMX001 in the 
monkey models avoids the differential PK and metabolism issues. As CDV-PP is the active antiviral 
metabolite that is common to both CMX001 and CDV, use of interspecies scaling through CDV-PP to 
extrapolate data from monkeys to humans is planned. Viruses 2010, 2                         
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In preliminary scaling studies, treatment with three doses of 20 mg/kg CMX001 has been shown to 
be effective in providing a survival benefit to rabbits infected with RPXV. In healthy rabbits, this 
treatment regimen resulted in an average CDV-PP concentration in PBMCs of 52.1 pg/10
6 cells when 
measured 24 hours after the third dose (Figure 2). Similarly, treatment with three doses of 20 mg/kg 
CDV has also shown efficacy in providing a survival benefit to monkeys infected with MPXV [44]. In 
healthy monkeys, this treatment regimen resulted in average CDV-PP concentrations in PBMCs in the 
range of 52.9 to 75.6 pg/10
6 cells when measured from 12 hours after the first dose to 48 hours after 
the  third  dose  (Figure  2).  Based  upon  these  results,  the  target  for  an  effective  intracellular 
concentration of CDV-PP is in the range of approximately 50 pg/10
6 cells as measured in PBMCs. 
Reliable CDV-PP concentration data in PBMCs of humans treated with CMX001 is currently not 
available for comparison; however, in vitro studies with human PBMCs indicate that these CDV-PP 
levels will be achieved with doses of CMX001 currently being studied in clinical trials for treatment of 
other dsDNA virus infections. For example, a dose of 2 mg/kg CMX001 in humans produced a Cmax of 
approximately 0.6 µM (350 ng/mL) and an AUC of approximately 2650 h·ng/mL CMX001 in plasma 
(CMX001-102). Isolated human PBMCs incubated with 0.1 µM CMX001 for 24 hours (estimated 
AUC = 1348 h·ng/mL) produced a concentration of CDV-PP of approximately 79 pg/10
6 cells at 
24 hours  which  is  within  the  expected  efficacious  range  as  estimated  from  rabbits  and  monkeys. 
Furthermore,  the  long  half-life  of  CDV-PP  observed  in  human  PBMCs  in  vitro  indicates  that 
infrequent  dosing  with  CMX001  is  sufficient  to  maintain  an  effective  intracellular  CDV-PP 
concentration. Additional studies measuring CDV-PP in the PBMCs of healthy and infected animals as 
well as in humans are planned. 
5. Toxicology of CMX001 
Twenty-six  toxicology  studies  have  been  conducted  to  describe  the  toxicological  profile  and 
secondary pharmacology of CMX001 to support its clinical development. Most studies employed dose 
administration by the oral route; however, CMX001 has also been administered to animals topically 
and by the intravenous, subcutaneous and intramuscular routes. Thirteen week studies in rats and 
cynomolgus  monkeys  have  been  completed  and  a  39-week  study  in  monkeys  is  ongoing.  Dose 
administration was daily in studies up to 14 days duration and twice weekly in the 13 and 39 week 
studies because it appeared that a longer dosing interval would provide relief from the dose-limiting 
gastrointestinal (GI) toxicity allowing administration of higher doses. Topical administration resulted 
in quantifiable systemic exposure and parenteral administration was not well tolerated due to injection 
site reactions and poor hemocompatibility.  
The dose-limiting toxicity of CMX001 is gastrointestinal. In general, decreased food consumption 
and corresponding decreases in body weight were the first signs of CMX001-related GI toxicity. In 
rats  given  a  single  100  mg/kg  dose,  these  signs  of  toxicity  appeared  two  to  three  days  after 
administration followed by dehydration, anorexia and nonformed/liquid/absent feces beginning six to 
eight days after administration. Histopathology changes in the GI were present as early as 24 hours 
after a 100 mg/kg dose, most severe at six to seven days post-dose, and fully resolved by 14 days  
post-dose. The histological findings were described as enteritis or enteropathy generally centered in 
the ileum or jejunum. In monkeys, gastropathy was also observed. Similar findings were observed at Viruses 2010, 2                         
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lower doses in repeat dose studies with daily administration for up to 14 days; however, no GI findings 
were observed in rats and monkeys administered CMX001 twice weekly for up to 13 weeks at doses of 
up  to  15  mg/kg  suggesting  an  extended  dosing  interval  allows  the  GI  time  to  recover  
between administrations.  
CMX001 produced other toxicities that have previously been reported for cidofovir. CMX001 was 
positive in the chromosomal aberrations assay but negative in the Ames and in vivo micronucleus tests. 
Like cidofovir, there was a dose-related incidence of mammary adenocarcinomas in rats administered 
CMX001 however, no tumors were observed in a similar study in monkeys and no excess risk of 
carcinogenicity has been reported in humans administered cidofovir. Also like cidofovir, CMX001 had 
effects on reproduction and development including decreased fertility. Embryotoxicity, malformations 
(skeletal and visceral), and developmental effects including decreased body weight gain and delayed 
sexual maturation were observed at doses that caused maternal toxicity. In general, doses that did not 
produce these effects were identified and the dosing regimen required to produce the effects was either 
more frequent or longer than is anticipated for treatment of smallpox.  
Although  CMX001  exposures  (AUC)  in  humans  were  higher  than  exposures  in  animals  at 
comparable doses, the toxicities observed in animals correlated with dose rather than with exposure 
(AUC) and are expected to be predictive of potential human toxicities despite differences in exposure. 
For example, no effect doses as well as doses that caused severe toxicity were the same in mice and 
monkeys even though exposures at a given dose were about 10-fold lower in monkeys compared with 
mice. To date, no dose-limiting toxicities have been observed in more than 300 patients administered 
CMX001 at doses that bracket the anticipated dose for smallpox given for durations of up to  six 
months  which  exceeds  the  anticipated  treatment  course  for  smallpox.  Exposures  in  humans  were 
higher than those observed in animals given similar doses, however, the doses were below those that 
caused dose-limiting toxicity in animals and the correlation with dose rather than exposure appears to 
be confirmed by the absence of any dose-limiting toxicities in humans administered CMX001 to date. 
The most significant point of distinction between the toxicity of CMX001 and that of CDV, is 
nephrotoxicity, the dose-limiting toxicity of Vistide®. The clinical utility of cidofovir is limited by a 
risk of acute nephrotoxicity necessitating in-hospital administration by intravenous infusion preceded 
by hydration and renal protection using probenecid. Numerous endpoints were incorporated in the 
nonclinical development of CMX001 to monitor for potential effects on the kidney, including changes 
in  serum  chemistry  (creatinine  and  BUN)  and  urinalysis  values,  changes  in  kidney  weight,  gross 
changes which included microscopic examination of the fresh cut (mid-line transverse section) surface 
of the kidney, and microscopic examination of fixed, stained sections by DACVP-certified veterinary 
pathologists. As judged by the absence of CMX001-related changes in any of these parameters, there 
was no evidence of cidofovir-like nephrotoxicity in any nonclinical study of CMX001. Hence, the 
dose-limiting toxicity of CMX001 appears to be gastrointestinal. In contrast to the nephrotoxicity 
produced by cidofovir, CMX001-related GI toxicity is easily monitored and rapidly reversible.  
5.1. Species Differences and Similarities in CMX001 Pharmacokinetics and Metabolism 
The pharmacokinetics of CMX001 has been evaluated in single and multiple dose studies in mice, 
rats, rabbits and cynomolgus monkeys [47,48]. CMX001 was readily absorbed in all species after oral Viruses 2010, 2                         
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administration, with lower systemic plasma concentrations observed in monkeys relative to other species 
including human (Table 4). The dose normalized exposure to CMX001 in humans (DN AUC0–∞) is more 
than 150-fold higher than that observed in monkeys. This difference is attributed, in part, to a higher 
rate of oxidative hepatic metabolism of CMX001 in monkeys. 
The  primary  mode  of  elimination  of  CMX001  is  via  metabolism,  based  on  lack  of  urinary 
elimination of CMX001 in animals and humans, as well as reasonably close predictions of in vivo 
clearance based on in vitro hepatocyte studies. After i.v. or oral administration of 
14C-CMX001 to 
monkeys or mice, less than 0.1% of the dose is excreted as unchanged parent drug in urine. After oral 
administration  of  CMX001  to  humans,  CMX001  was  below  detection  in  most  urine  samples.  
After in vitro incubation with cryopreserved suspended hepatocytes, 
14C-CMX001 was degraded more 
rapidly when incubated with cynomolgus or rhesus monkey hepatocytes than when incubated with 
rabbit or human hepatocyte incubations. Using intrinsic clearance obtained from this study to predict 
in  vivo  clearance  based  on  the  well-stirred  model  of  hepatic  clearance  [49],  a  reasonably  close 
prediction of cynomolgus monkey clearance is obtained (actual mean  clearance values 22 and 25 
mL/min/kg after i.v. administration of 1 and 4 mg/kg CMX001 to cynomolgus monkeys, respectively, 
compared to predicted 19 mL/min/kg), further supporting that metabolism by the liver is a major route 
of elimination for CMX001 [50]. The predicted versus actual clearance values for rabbits were 11 
versus 16 mL/min/kg (i.v. administration of 4 mg/kg) and for humans were 6 versus 13 mL/min/kg 
(oral administration of 2 mg/kg). 
The  qualitative  in  vitro  and  in  vivo  metabolite  profile  was  similar  across  species,  though  the 
quantities of metabolites differed between species. After incubation of 
14C-CMX001 with mouse, rat, 
rabbit,  monkey  and  human  hepatocytes,  the  major  metabolites  determined  by  HPLC-MS-MS  and 
radiochemical detection included CDV, CMX103 (3-(4-butanoic acid)propyl hydrogen ((S)-1-(4-amino-
2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yloxy)methylphosphonate),  CMX064  (3-hydroxypropyl 
hydrogen  ((S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yloxy)methylphosphonate); 
CMX108  (monohydroxylation  on  hexadecyl  alkyl  chain);  and  CMX108  glucuronide  [50].  After 
administration of 
14C-CMX001 to cynomolgus monkeys, the major metabolite in plasma and excreta 
was  identified  as  CMX064;  CDV,  CMX103  and  four  additional  oxidative  metabolites  (lipid 
chain-shortened carboxylic acids) were also detected in plasma and excreta by HPLC-MS-MS. After 
administration of 
14C-CMX001 to mice, the major metabolite in plasma and excreta was CMX103, 
with  lesser  amounts  of  CDV  and  CMX064  also  present.  The  concentrations  of  six  metabolites 
(previously identified in animal ADME studies) were quantified in plasma samples following oral 
administration  of  CMX001  to  humans  (Clinical  Study  CMX001-103).  The  three  major  human 
metabolites were CMX103 (130% of CMX001 AUC), CDV (90% of CMX001 AUC) and CMX064 
(50% of CMX001 AUC). The enzymes responsible for metabolism of CMX001 have not been fully 
elucidated. However, upon incubation of 
14C-CMX001 with human hepatocytes in the presence of the 
cytochrome P450 (CYP) inhibitor, 1-aminobenztriazole, the amount of CMX103 formed was reduced 
by approximately 50%, suggesting that the formation of CMX103 was partially mediated by CYP 
enzymes [51].  Viruses 2010, 2                         
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5.2. OAT-mediated Secretion and Kidney Distribution  
CDV  is  actively  secreted  from  blood  into  kidney  proximal  tubule  cells  by  the  organic  anion 
transporters (OATs), leading to  high concentrations in kidney proximal tubules and CDV-induced 
nephrotoxicity [52]. As shown in Figure 3 and in contrast to CDV, CMX001 uptake is not enhanced  
in vitro in cells expressing OAT1 compared to control cells that do not express this transporter (net 
uptake is approximately zero, after incubation with OAT1-expressing cells and non-OAT1-expressing 
control cells at a concentration of 5 µM of test drug for 5 min), nor is uptake reduced by the OAT 
inhibitor probenecid. These results indicate that CMX001 is not a substrate for OATs [53]. 
Figure 3. Uptake of CMX001 and CDV in OAT1-expressing cells in vitro. 
 
 
The distribution of radioactivity to the kidney seen in mice following administration of CMX001 is 
supportive of these in vitro findings. Peak concentrations of radioactivity in kidney cortex, the tissue 
which  contains  renal  proximal  tubules,  was  more  than  30-fold  lower  after  oral  administration  of 
5 mg/kg 
14C-CMX001 compared to that observed after i.v. administration of an equivalent dose of 
14C-CDV. In addition, the tissue:plasma ratio in kidney cortex ranged from 4:1 at the time of peak 
concentration (4 h), and increased to 25:1 at 48 h after CMX001 administration compared to much 
higher ratios following i.v. cidofovir (21:1 at the time of peak concentration (0.5 h), with an increase  
to  400:1,  4  h  after  cidofovir  administration).  Thus,  CMX001  has  a  low  potential  to  cause 
CDV-induced nephrotoxicity because it is not itself a substrate for OATs [54]. 
6. Clinical Experience with CMX001 
CMX001 is currently in clinical development for the prophylaxis and treatment of multiple dsDNA 
viral  infections  including:  (1)  the  treatment  of  smallpox  under  the  ―Animal  Rule‖  using  animal 
efficacy data and human safety data, (2) prophylaxis/preemption of cytomegalovirus disease in human 
stem cell transplant (HSCT) recipients, and (3) preemption treatment of adenovirus disease in pediatric 
HSCT  recipients.  CMV  and  AdV  are  common,  typically  mild  and  self-limited,  infections  in  the Viruses 2010, 2                         
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healthy  host,  but  cause  life-  and  graft-threatening  disease  in  transplant  patients  as  well  as  severe 
opportunistic infections in other immunocompromised individuals. 
The demonstration of safety and efficacy of CMX001 in humans with these life-threatening dsDNA 
virus infections can provide critical supportive data for the registration package for the treatment of 
smallpox under the Animal Rule. In draft guidance for industry entitled ―Smallpox (Variola) Infection: 
Developing Drugs for the Treatment or Prevention‖ published in November of 2007, FDA states that 
―because smallpox is no longer a naturally occurring disease, data from studies of a candidate in other 
human illnesses might play a more important role than usual in the evaluation of drug safety.‖ In this 
same guidance FDA also states that human data are particularly compelling if they involve the study of 
―viral  infections  related  to  variola.‖  Certainly  in  the  case  of  CMX001,  pharmacokinetic  and 
pharmacodynamic parameters for doses that demonstrate clinical efficacy for the treatment of dsDNA 
viral  infections  can  be  compared  directly  to  pharmacokinetic  and  pharmacodynamic  parameters 
necessary for the prevention of mortality in animal models of human smallpox (i.e., animals infected 
with dsDNA viruses in the family Orthopoxviridae). This comparison will validate that drug exposures 
necessary to treat smallpox can be achieved in humans and that these doses are efficacious in humans 
as evidenced by activity against similar dsDNA virus infections. 
CMX001 has been administered to healthy human volunteers in two completed Phase 1 clinical 
trials (designated CMX001-102 and CMX001-103). Two clinical trials are ongoing: a Phase 1b/2a trial 
(CMX001-104)  in  renal  and  hematopoietic  stem  cell  transplants  (HSCT)  patients  with  BK  virus 
viruria,  and  a  Phase  2  trial  (CMX001-201)  in  HSCT  recipients  to  evaluate  CMX001  for  the 
prophylaxis and/or pre-emptive treatment of CMV infection in this population. In addition over 105 
patients  have  been  treated  for  various  dsDNA  virus  infections  under  Emergency  INDs  or  the  
ex-US equivalent. 
6.1. CMX001-102 
CMX001–102 was a Phase 1, dose-escalation, pharmacokinetic (PK), first time in humans (FTIH) 
study of the safety and tolerability of CMX001 in healthy human volunteers. A solution formulation of 
CMX001 was administered as a weight-based dose to volunteers in a total of nine single dose cohorts 
(.025, .05, 0.1, 0.2, 0.4, 0.6, 1, 1.5 and 2 mg/kg) and five multiple dose cohorts (0.1, 0.2, 0.4, 0.6 and 
1.0 mg/kg). Subjects in the multiple dose cohorts received a total of three doses of CMX001, one dose 
every six days. Each cohort enrolled six subjects randomized 2:1 (active: placebo). Following the 
completion  of  each  cohort,  all  safety  data  and  subsequent  dose  escalations  were  reviewed  and 
approved by a Data Safety Monitoring Board (DSMB) and the FDA. Safety analysis included clinical 
and laboratory assessments as well as wireless capsule endoscopy (WCE) which was conducted before 
and after dosing to look for macroscopic evidence of GI toxicity. 
There  were  no  severe  adverse  events  (SAEs),  no  adverse  events  (AEs)  that  prevented  dose 
escalation, and no evidence of GI toxicity. A total of 30 treatment-emergent adverse events were 
reported by 16 subjects (30% of subjects who received at least one dose of CMX001 or placebo). 
Among the 36 subjects who received CMX001, nine (25%) subjects reported at least one adverse 
event and among the 18 subjects who received placebo, seven (39%) subjects reported at least one 
adverse event. No dose-related trend in the incidence or severity of AEs was observed.  Viruses 2010, 2                         
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After  a  single  dose  under  fasting  conditions,  CMX001  was  readily  absorbed  with  the  time  to 
maximum  plasma  concentration  (Tmax)  ranging  from  two  to  three  hours.  Maximum  plasma 
concentration (Cmax) and systemic exposure (AUC) increased approximately in proportion to dose over 
the range of 0.025 to 2.0 mg/kg. The half-life of elimination (t1/2 elim) increased with increasing dose, 
ranging from 6.15 hours at 0.025 mg/kg to 32.7 hours at 1.5 mg/kg, presumably due to better definition 
of  the  elimination  phase  at  higher  doses.  CMX001  is  not  eliminated  in  urine;  however,  CDV,  a 
metabolite of CMX001 is eliminated in urine. No changes in PK parameters were observed after repeat 
administration. 
6.2. CMX001-103 
CMX001-103 was a Phase 1 comparative bioavailability study of CMX001 solution versus tablets, 
plus a comparison of PK parameters for CMX001 and CDV in subjects administered CMX001 after 
fasting overnight versus having eaten a high fat meal within 30 minutes of dosing. CMX001 was 
administered as a fixed dose to 24 volunteers in three single doses (40 mg solution, fasted; 40 mg 
tablet following a high fat breakfast; and 40 mg tablet fasted). Each dose was separated by a 14-day 
washout period. 
CMX001 was generally safe and well tolerated by healthy volunteers. The most frequently reported 
adverse  events  were  headache  (17%),  increased  blood  CPK  (17%),  increased  ALT  (13%),  
nausea (8%), and oropharyngeal pain (8%). This study showed that CMX001 administered as a tablet 
in  the  fasted  state  produces  similar  Cmax  and  AUC  values  to  those  observed  after  CMX001 
administration as solution in the fasted state, and that CMX001 administered as tablet in the fed state 
as compared with the fasted state demonstrates a significant food effect as evidenced by decreased 
Cmax, AUC∞ and AUClast values. Peak plasma concentrations (Cmax) and systemic exposure (AUC0–∞) 
following administration in the fed state were reduced approximately 48% and 28%, respectively, 
compared with Cmax and AUC0–∞ following administration to fasted subjects. In addition, the median 
time to peak plasma concentrations in fed subjects was approximately twice that for fasted subjects. 
Changing  the  dose  formulation  from  solution  to  tablet  may  reduce  exposure  to  CMX001  by  a 
maximum of approximately 13%. 
6.3. CMX001-104 
CMX001-104, a study of the safety, tolerability, and preliminary antiviral activity of CMX001 in 
renal transplant and HSCT recipients with BK viruria, is nearing completion. A total of twenty-eight 
subjects were enrolled into this study. All received fixed doses of 10, 20, or 40 mg of CMX001 or 
placebo once or twice weekly for up to 28 days. No serious adverse events attributable to study drug 
(i.e., CMX001 or placebo) have been reported. 
6.4. CMX001-201 
CMX001-201, a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study 
of the safety, tolerability, and ability of CMX001 to prevent or control post-transplant CMV infection 
in CMV seropositive HSCT recipients is underway. Up to 6 dose-escalation cohorts of 32 subjects per Viruses 2010, 2                         
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cohort are planned. An expansion phase of this study is also planned to enroll up to 200 patients at a 
dose assessed during the dose-escalation phase and selected based on preliminary safety and efficacy. 
The  expansion  phase  will  increase  enrollment  at  the  selected  dose  to  obtain  the  statistical  power 
needed to show a difference in efficacy between CMX001 and placebo in the prevention of CMV. 
Forty subjects were enrolled in cohort 1 and 39 subjects were enrolled in cohort 2. Subjects were 
randomized 3:1 to receive once weekly doses of 40 mg (cohort 1) or 100 mg (cohort 2) of CMX001 or 
matching  placebo.  Treatment  with  study  drug  was  continued  for  up  to  90  days  (or  13  weeks) 
post-transplant. Enrollment into cohort 3, at  a once weekly dose of 200 mg CMX001 or placebo  
is ongoing. 
6.5. Emergency IND Experience 
Additional clinical experience with CMX001 has been gained through the emergency treatment of 
various dsDNA virus infections under Emergency IND (EIND) or ex-US equivalent [55–57]. More 
than 105 patients have received CMX001 through emergency single patient protocols. Patients from 
one month to 69 years of age have been treated, with the longest treatment duration in excess of six 
months. Results of the EIND experience have been reported for the use of CMX001 to treat recurrent 
CMV (a case series involving three transplant patients who had failed valganciclovir therapy), AdV 
infection (a case series of thirteen immunocompromised patients with a median age of 12 years, range 
0.75  to  66,  with  disseminated  AdV  infection)  and  progressive  vaccinia  (a  single  case  with 
complications from smallpox vaccination). For example, AdV viremia declined by almost 1000-fold 
(2.9 log10) in patients who received eight weeks of CMX001 therapy [55].  
In an analysis of pharmacokinetic data from 49 patients treated under EINDs with CMX001, higher 
clearance resulting in lower systemic exposure (AUC0–∞) was observed in pediatric (age ≤ 18 years) 
patients relative to adults at doses of 2, 3 and 4 mg/kg. At a given dose, pediatric patients typically  
had 30% to 50% of the average adult exposure. In both pediatric and adult patients, Cmax and AUC0–∞ 
generally increased greater than in proportion to dose. In a second analysis conducted separately for 
both pediatric and adult patients, systemic exposure to CMX001 was comparable between patients 
with normal renal function and those with moderate to severe renal impairment, in both the pediatric 
and adult populations, indicating that dose adjustment is not needed in patients with renal impairment. 
In this analysis, it was found that CMX001 exposure is not affected by hemodialysis [48]. 
6.6. Additional Studies in Planning Stage 
Two  additional  clinical  studies  are  under  development.  A  randomized,  double-blind, 
placebo-controlled study evaluating the safety and efficacy of pre-emptive treatment with CMX001 in 
children for the prevention of AdV disease following HSCT is planned. Also, a multicenter, open-label 
study of CMX001 treatment of serious diseases or conditions caused by dsDNA viruses is in the initial 
stages of enrollment. In the open-label study, up to 200 patients without viable alternatives, including 
other studies of CMX001, will be enrolled for the treatment of diseases caused by poxviruses (vaccinia 
virus and molluscum contagiosum), adenoviruses, herpesviruses (CMV, HSV, EBV, VZV, HHV6), 
polyomaviruses (BKV or JCV), and HPV. Treatment with CMX001 in this protocol may be continued 
twice weekly for up to six months, as needed, based on the clinical disease state of the patient. Viruses 2010, 2                         
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7. Conclusions 
CMX001 has demonstrated in vitro and in vivo efficacy against orthopoxvirus infections. In the 
rabbitpox model it significantly improved survival even when administered after lesions were detected. 
Although  the  antiviral  activity  of  CMX001  is  not  evaluable  in  monkeys  due  to  species  specific 
metabolism/anabolism issues which result in low intracellular levels of the active antiviral, CDV is an 
effective  surrogate  for  CMX001  and  scaling  animal  results  to  humans  via  CDV-PP  should  allow 
development to proceed using the variola model in monkeys combined with proof of efficacy against 
similar dsDNA virus infections in humans. Current data suggest the 2 mg/kg dose of CMX001 which 
has been used to treat dsDNA virus infections in patients should produce CDV-PP levels above those 
attained  in  rabbits  dosed  with  levels  of  CMX001  which  effectively  prevented  mortality  after 
appearance  of  lesions.  The  reductions  in  adenovirus  viremia  reported  in  EIND  patients  following 
treatment with CMX001 provide further support for potential human efficacy from a non-orthopox 
dsDNA virus model that has important similarities to VARV, including disseminated, lytic infection of 
epithelial cells. The emerging efficacy, safety, pharmacokinetic and resistance profiles of CMX001 
make it a promising antiviral for use in the treatment of smallpox. 
Acknowledgements 
This work was supported in part by NIAID grant U01 AI057233-01. 
References and Notes 
1.  Breman, J.G.; Henderson, D.A. Diagnosis and management of smallpox. N. Engl. J. Med. 2002, 
346, 1300–1308. 
2.  Fenner, F.; Henderson, D.A.; Arita, I.; Jezek, Z.; Ladnyi, I.D. Smallpox and its Eradication; 
World Health Organization: Geneva, Switzerland, 1988. 
3.  Meltzer, M.I. Risks and benefits of preexposure and postexposure smallpox vaccination. Emerg. 
Infect. Dis. 2003, 9, 1363–1370. 
4.  Tucker, J. Scourge: The Once and Future Threat of Smallpox; Altantic Monthly Press: New 
York, NY, USA, 2006. 
5.  Chen, N.; Bellone, C.J.; Schriewer, J.; Owens, G.; Frederickson, T.; Parker, S.; Buller, R.M.L. 
Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: 
Pathogenesis, prophylaxis and antiviral therapy. Virology 2010, doi:10.1016/j.virol.2010.10.02. 
Available  online:  http://www.sciencedirect.com/science/journal/00426822  (accessed  10 
November 2010). 
6.  Ross, E.M. Pharmacodynamics: Mechanisms of Drug Action and the Relationship Between Drug 
Concentration  and  Effect.  In  Goodman  and  Gilman’s  The  Pharmacological  Basis  of 
Therapeutics; Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W., Gilman, A.G., Eds.; 
McGraw-Hill: New York, NY, USA, 1996; pp. 29–42. 
7.  Balzarini, J.; Naesens, L.; De Clercq, E. New antivirals—Mechanism of action and resistance 
development. Curr. Opin. Microbiol. 1998, 1, 535–546. Viruses 2010, 2                         
 
 
2759 
8.  Painter, G.R.; Hostetler, K.Y. Design and development of oral drugs for the prophylaxis and 
treatment of smallpox infection. Trends Biotechnol. 2004, 22, 423–427. 
9.  Connelly, M.C.; Robbins, B.L.; Fridland, A. Mechanism of uptake of the phosphonate analog 
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine  (HPMPC)  in  Vero  cells.  Biochem. 
Pharmacol. 1993, 46, 1053–1057. 
10.  Cihlar,  T.;  Chen,  M.S.  Identification  of  enzymes  catalyzing  two-step  phosphorylation  of 
cidofovir  and  the  effect  of  cytomegalovirus  infection  on  their  activities  in  host  cells.  Mol. 
Pharmacol. 1996, 50, 1502–1510. 
11.  Chou,  S.;  Lurain,  N.S.;  Thompson,  K.D.;  Miner,  R.C.;  Drew,  W.L.  Viral  DNA  polymerase 
mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 2003, 188, 
32–39. 
12.  Kinchington, P.R.; Araullo-Cruz, T.; Vergnes, J.P.; Yates, K.; Gordon, Y.J. Sequence changes in 
the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum 
antiviral cidofovir. Antivir. Res. 2002, 56, 73–84. 
13.  Magee, W.C.; Aldern, K.A.; Hostetler, K.Y.; Evans, D.H. Cidofovir and (S)-9-[3-hydroxy-(2-
phosphonomethoxy)propyl]adenine  are  highly  effective  inhibitors  of  vaccinia  virus  DNA 
polymerase when incorporated into the template strand. Antimicrob. Agents Chemother. 2008, 
52, 586–597. 
14.  Xiong, X.; Smith, J.L.; Chen, M.S. Effect of incorporation of cidofovir into DNA by human 
cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 1997, 
41, 594–599. 
15.  Poxvirus Bioinformatics Resource Center. Available online: http://www.poxvirus.org (accessed 
on 22 January 2009). 
16.  Altschul, S.F.; Madden, T.L.; Schaffer, A.A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D.J. 
Gapped  BLAST  and  PSI-BLAST:  A  new  generation  of  protein  database  search  programs. 
Nucleic. Acids Res. 1997, 25, 3389–3402. 
17.  Hartline, C.B.; Gustin, K.M.; Wan, W.B.; Ciesla, S.L.; Beadle, J.R.; Hostetler, K.Y.; Kern, E.R. 
Ether  lipid-ester  prodrugs  of  acyclic  nucleoside  phosphonates:  Activity  against  adenovirus 
replication in vitro. J. Infect. Dis. 2005, 191, 396–399. 
18.  Williams-Aziz, S.L.; Hartline, C.B.; Harden, E.A.; Daily, S.L.; Prichard, M.N.; Kushner, N.L.; 
Beadle, J.R.; Wan, W.B.; Hostetler, K.Y.; Kern, E.R. Comparative activities of lipid esters of 
cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob. Agents 
Chemother. 2005, 49, 3724–3733. 
19.  Christensen, N. Penn State College of Medicine, Hershey, PA, USA. Study report, 2007. 
20.  Randhawa,  P.;  Farasati,  N.A.;  Shapiro,  R.;  Hostetler,  K.Y.  Ether  lipid  ester  derivatives  of 
cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob. Agents Chemother. 2006, 50, 
1564–1566. 
21.  Jiang, Z.G.; Cohen, J.;  Marshall,  L.J.;  Major,  E.O. Hexadecyloxypropyl-cidofovir, CMX001, 
suppresses  JC  virus  replication  in  human  fetal  brain  SVG  cell  cultures.  Antimicrob.  Agents 
Chemother. 2010, 54, 4723–4732. 
22.  Huggins, J.W.; Baker, R.O.; Beadle, J.R.; Hostetler, K.Y. Orally active ether lipid prodrugs of 
cidofovir for the treatment of smallpox. Antivir. Res. 2002, 53, A66, abstract 104. Viruses 2010, 2                         
 
 
2760 
23.  Kern, E.R.; Hartline, C.; Harden, E.; Keith, K.; Rodriguez, N.; Beadle, J.R.; Hostetler, K.Y. 
Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and 
cyclic cidofovir. Antimicrob. Agents Chemother. 2002, 46, 991–995. 
24.  Buller, R.M.; Owens, G.; Schriewer, J.; Melman, L.; Beadle, J.R.; Hostetler, K.Y. Efficacy of oral 
active ether lipid analogs of cidofovir in a lethal mousepox model. Virology 2004, 318, 474–481. 
25.  Prichard,  M.N.  University  of  Alabama,  Birmingham,  AL,  USA.  Personal  communication  by 
email, 2010. 
26.  Smee, D.F.; Sidwell, R.W.; Kefauver, D.; Bray, M.; Huggins, J.W. Characterization of wild-type 
and  cidofovir-resistant  strains  of  camelpox,  cowpox,  monkeypox,  and  vaccinia  viruses. 
Antimicrob. Agents Chemother. 2002, 46, 1329–1335. 
27.  Kornbluth, R.S.; Smee, D.F.; Sidwell, R.W.; Snarsky, V.; Evans, D.H.; Hostetler, K.Y. Mutations 
in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the 
drug resistance phenotype. Antimicrob. Agents Chemother. 2006, 50, 4038–4043. 
28.  Andrei, G.; Gammon, D.B.; Fiten, P.; De Clercq, E.; Opdenakker, G.; Snoeck, R.; Evans, D.H. 
Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 2006, 
80, 9391–9401. 
29.  Becker,  M.N.;  Obraztsova,  M.;  Kern,  E.R.;  Quenelle,  D.C.;  Keith,  K.A.;  Prichard,  M.N.;  
Luo,  M.;  Moyer,  R.W.  Isolation  and  characterization  of  cidofovir  resistant  vaccinia  viruses. 
Virol. J. 2008, 5, 58. 
30.  Gammon, D.B.; Snoeck, R.; Fiten, P.; Krecmerova, M.; Holy, A.; De Clercq, E.; Opdenakker, 
G.;  Evans,  D.H.;  Andrei,  G.  Mechanism  of  antiviral  drug  resistance  of  vaccinia  virus: 
Identification  of  residues  in  the  viral  DNA  polymerase  conferring  differential  resistance  to 
antipoxvirus drugs. J. Virol. 2008, 82, 12520–12534. 
31.  Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. Code of 
Federal Regulations, Part 314, Subpart I, Title 21, 2002. 
32.  Painter, G.R.; Trost, L.C.; Lampert, B.M.; Almond, M.R.; Buller, M.; Kern, E.; Painter, G.P.; 
Robertson, A.T.; Frazer, N.; O'Mahony, R. CMX001. Anti-smallpox agent, anti-cytomegalovirus 
agent, viral polymerase inhibitor. Drugs Future 2010, 33, 655–661. 
33.  Franz,  D.R.;  Jahrling,  P.B.;  Friedlander,  A.M.;  McClain,  D.J.;  Hoover,  D.L.;  Bryne,  W.R.; 
Pavlin,  J.A.;  Christopher,  G.W.;  Eitzen,  E.M.,  Jr.  Clinical  recognition  and  management  of 
patients exposed to biological warfare agents. JAMA 1997, 278, 399–411. 
34.  Parker, S.; Siddiqui, A.M.; Painter, G.; Schriewer, J.; Buller, R.M. Ectromelia virus infections of 
mice as a model to support the licensure of anti-orthopoxvirus therapeutics. Viruses 2010, 2, 
1918–1932. 
35.  Buller, R.M.L. Saint Louis University, Saint Louis, MO, USA. Study report, 2009. 
36.  Parker, S.; Touchette, E.; Oberle, C.; Almond, M.; Robertson, A.; Trost, L.C.; Lampert, B.; 
Painter, G.; Buller, R.M. Efficacy of therapeutic intervention with an oral ether-lipid analogue of 
cidofovir (CMX001) in a lethal mousepox model. Antivir. Res. 2008, 77, 39–49. 
37.  Quenelle,  D.C.;  Collins,  D.J.;  Wan,  W.B.;  Beadle,  J.R.;  Hostetler,  K.Y.;  Kern,  E.R.  Oral 
treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. 
Antimicrob. Agents Chemother. 2004, 48, 404–412. Viruses 2010, 2                         
 
 
2761 
38.  Adams, M.M.; Rice, A.D.; Moyer, R.W. Rabbitpox virus and vaccinia virus infection of rabbits 
as a model for human smallpox. J. Virol. 2007, 81, 11084–11095. 
39.  Westwood,  J.C.N.;  Boulter,  E.A.;  Bowen,  E.T.W.;  Maber,  H.B.  Experimental  respiratory 
infection with poxviruses. I. Clinical virological and epidemiological studies. Br. J. Exp. Pathol. 
1966, 47, 453–465. 
40.  Rice, A.D.; Adams, M.M.; Wallace, G.; Burrage, A.M.; Lindsey, S.F.; Smith, A.J.; Swetnam, D.; 
Manning,  B.R.;  Gray,  S.A.;  Lampert,  B.;  Foster,  S.;  Lanier,  R.;  Robertson,  A.;  Painter,  G.; 
Moyer, R.W. Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits 
infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 2010, 
(submitted for publication). 
41.  Rice, A.D.; Adams, M.M.; Lampert, B.; Foster, S.; Lanier, R.; Robertson, A.; Painter, G.R.; 
Moyer, R.W. Efficacy of CMX001 as a Prophylactic and presymptomatic antiviral agent in New 
Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of 
humans. Viruses 2010, (submitted for publication). 
42.  Earl, P.L.; Americo, J.L.; Wyatt, L.S.; Eller, L.A.; Whitbeck, J.C.; Cohen, G.H.; Eisenberg, R.J.; 
Hartmann,  C.J.;  Jackson,  D.L.;  Kulesh,  D.A.;  Martinez,  M.J.;  Miller,  D.M.;  Mucker,  E.M.; 
Shamblin,  J.D.;  Zwiers,  S.H.;  Huggins,  J.W.;  Jahrling,  P.B.;  Moss,  B.  Immunogenicity  of  a 
highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428, 
182–185. 
43.  Hooper,  J.W.;  Thompson,  E.;  Wilhelmsen,  C.;  Zimmerman,  M.;  Ichou,  M.A.;  Steffen,  S.E.; 
Schmaljohn, C.S.; Schmaljohn, A.L.; Jahrling, P.B. Smallpox DNA vaccine protects nonhuman 
primates against lethal monkeypox. J. Virol. 2004, 78, 4433–4443. 
44.  Huggins, J.W.; Martinez, M.J.; Hartmann, C.J.; Hensley, LE.; Jackson, D.L.; Kefauver, D.F.; 
Kulesh, D.A.; Larsen, T.; Miller, D.M.; Mucker, E.M.; Shamblin, J.D.; Tate, M.K.; Whitehouse, 
C.A.;  Zwiers, S.H.; Jahrling, P.B. Successful cidofovir treatment of smallpox-like disease in 
Variola and monkeypox primate models. Antivir. Res. 2004, 62, A57–A56. 
45.  Marriott, K.A.; Parkinson, C.V.; Morefield, S.I.; Davenport, R.; Nichols, R.; Monath, T.P. Clonal 
vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge. 
Vaccine 2008, 26, 581–588. 
46.  Franz, D.R.; Jahrling, P.B.; McClain, D.J.; Hoover, D.L.; Byrne, W.R.; Pavlin, J.A.; Christopher, 
G.W.; Cieslak, T.J.; Friedlander, A.M.; Eitzen, E.M., Jr. Clinical recognition and management of 
patients exposed to biological warfare agents. Clin. Lab. Med. 2001, 21, 435–473. 
47.  Lampert, B.M.; Almond, M.A.; Trost, L.C. Species-dependent pharmacokinetics of CMX001, an 
orally-available prodrug of cidofovir being developed for treatment of poxvirus infection. In 
Proceeding of the 47th SOT Annual Meeting, Seattle, WA, USA, 16–20 March 2008. 
48.  Trost, L.C.; Tippin, T.K.; Anderson, M.A.; Painter, W.P. Compromised renal function does not 
affect  the  pharmacokinetics  of  CMX001  in  patients  with  severe  double-stranded  DNA  virus 
infections. In Proceeding of the 50th Annual Interscience Conference on Antimicrobial Agents 
and Chemotherapy, Boston, MA, USA, 12–15 September 2010.  
49.  Obach, R.S.; Baxter, J.G.; Liston, T.E.; Silber, B.M.; Jones, B.C.; MacIntyre, F.; Rance, D.J.; 
Wastall, P. The prediction of human pharmacokinetic parameters from preclinical and in vitro 
metabolism data. J. Pharmacol. Exp. Ther. 1997, 283, 46–58. Viruses 2010, 2                         
 
 
2762 
50.  Tippin,  T.K.;  Almond,  M.R.;  Painter,  G.R.;  Lampert,  B.M.  In  vitro  hepatic  metabolism  of 
CMX001, a lipid conjugate of cidofovir. Drug Metab. Rev. 2009, 41 (Supplement 3), 149. 
51.  Tippin,  T.K.;  Lampert,  B.M.;  Robertson,  A.;  Anderson,  M.;  Almond,  M.R.;  Painter,  G.R.;  
Trost, L.C. Differences in monkey and human pharmacokinetics and metabolism of CMX001, a 
lipid conjugate of cidofovir. Antimicrob. Agents Chemother. 2010, to be submitted for publication. 
52.  Ho, E.S.; Lin, D.C.; Mendel, D.B.; Cihlar, T. Cytotoxicity of antiviral nucleotides adefovir and 
cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. 
Nephrol. 2000, 11, 383-393. 
53.  Tippin,  T.K.;  Lampert,  B.M.;  Painter,  G.P.;  Lanier,  R.  Lipid  conjugates  of  cidofovir  and 
tenofovir, CMX001 and CMX157, are not substrates of human organic anion transporters OAT1 
and  OAT3.  In  Proceeding  of  the  American  Association of  Pharmaceutical Scientists  Annual 
Meeting, New Orleans, LA, USA, 14–18 November 2010. 
54.  Tippin, T.K.; Lampert, B.; Painter, G.; Lanier, R. CMX001, a lipid conjugate of cidofovir:  Lack 
of human organic anion transporter-mediated uptake in vitro and reduced kidney distribution in 
mice compared to cidofovir. J. Pharmacol. Exp. Ther. 2010, to be submitted for publication. 
55.  Florescu,  D.F.;  Igdon,  J.;  Pergam,  S.A.;  Neely,  M.;  Johnston,  C.;  Way,  S.S.;  Sande,  J.; 
Lewinsohn, D.; Guzman-Cottrill, J.; Kurtzberg, J.; Papanicolaou, G.; Graham, M.L.; Painter, W.; 
Lanier, R.; Mommeja-Marin, H.; Anderson, M.; van der Horst, C. Experience with CMX001, a 
novel antiviral drug, for adenovirus infections in immunocompromised patients. In Proceeding of 
the IDSA 48th Annual Meeting, Vancouver, BC, Canada, 21–24 October 2010. 
56.  Centers  for  Disease  Control  and  Prevention.  Progressive  vaccinia  in  a  military  smallpox 
vaccinee―United States, 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58, 532–536. 
57.  Painter, W.; Mossad, S.; Siemionow, M.; Eghtesad, B.; Djohan, R.; Papay, F.; Avery, R. First use 
of CMX001, a novel antiviral drug, for the suppression of cytomegalovirus infection in solid 
organ  transplant  patients:  A  case  series.  Am.  J.  Transplant.  2010,  10  (Supplement  4),  211 
(Abstract# LB10). 
© 2010  by the  authors;  licensee  MDPI, Basel, Switzerland.  This  article  is an open access article 
distributed  under  the  terms  and  conditions  of  the  Creative  Commons  Attribution  license 
(http://creativecommons.org/licenses/by/3.0/). 